S 1040 · 119th Congress 2025–2027

Drug Competition Enhancement Act

Latest action · Apr 10, 2025 Placed on Senate Legislative Calendar under General Orders. Calendar No. 43.

Progress

Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.

  1. IntroducedMar 13, 2025
  2. Passed SenateNot reached
  3. Passed HouseNot reached
  4. To the PresidentNot reached
  5. Became lawNot reached

Summary

Drug Competition Enhancement Act

This bill prohibits product hopping by drug manufacturers and authorizes the Federal Trade Commission (FTC) to enforce this prohibition.

Generally, product hopping describes a situation where, when the patents on a reference drug (or biological product) expire, the manufacturer switches to a follow-on product that is covered by a later-expiring patent. Under this bill, a follow-on product is a modified version of the reference drug that has an indication (what the drug is used for) that is identical or substantively similar to an indication of the reference drug.

The bill establishes a presumption that product hopping has occurred when a reference drug manufacturer, after receiving notice that the Food and Drug Administration has received an application to market a competing generic (or biosimilar) version, takes certain actions such as withdrawing the reference drug from the market and selling a follow-on product.

A drug manufacturer may rebut these presumptions by demonstrating that its conduct was not intended to limit competition.

The bill makes product hopping an unfair method of competition and provides for enforcement by the FTC. If the FTC has reason to believe a manufacturer has violated or is about to violate this prohibition on product hopping, the FTC may institute an administrative proceeding or bring suit in federal court to stop the manufacturer’s action and seek equitable remedies, including disgorgement of unjust profits or paying restitution to those harmed. 

Cosponsors 3

Members who signed on, in the order they did. All signed on Mar 13, 2025.

SeatCosponsorSigned on
R-IAChuck GrassleyOriginalMar 13, 2025
D-CTRichard BlumenthalOriginalMar 13, 2025
D-ILRichard J. DurbinOriginalMar 13, 2025

Committees 1

Where it was sent and what each committee and subcommittee did with it, in order.

ChamberCommitteeWhat it did
SenateJudiciary Committee
Referred Mar 13, 2025Markup Apr 3, 2025Reported Apr 10, 2025

Actions 5

Everything that happened, newest first.

  1. Apr 10, 2025Committee on the Judiciary. Reported by Senator Grassley with an amendment. Without written report.
  2. Apr 10, 2025Placed on Senate Legislative Calendar under General Orders. Calendar No. 43.
  3. Apr 3, 2025Committee on the Judiciary. Ordered to be reported with an amendment favorably.
  4. Mar 13, 2025Introduced in Senate
  5. Mar 13, 2025Read twice and referred to the Committee on the Judiciary.

Research

What has been written about this bill: committee reports, cost estimates, the sponsor’s authority statement, printed hearings and the Congressional Research Service’s work.

CRS reports 1

Congressional Research Service work that CRS links to this bill or the law it became, newest first.

Cite it 1

Products on other subjects that cite it, usually among other measures.

ProductTitleKindPublished
R48482Science and Technology Issues for the 119th CongressReportApr 2, 2026

Titles 3

Every title it has carried, official and short, at each stage.

Official Title as Introduced
A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes.
Short Title(s) as Introduced
Drug Competition Enhancement Act
Short Title(s) as Reported to Senate
Drug Competition Enhancement Act

Subjects

Assigned by the Library of Congress. Policy area: Health.

Text 2

Each version as it was printed, newest first.

  1. Apr 10, 2025Reported to Senate
  2. Mar 13, 2025Introduced in Senate

Support LegiList

This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.

Processed by Stripe in a separate window. LegiList never sees card details.

Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.